Yazar "Barh, Debmalya" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • Küçük Resim Yok
    Öğe
    Breast cancer stem cells and cellomics
    (Springer India, 2014) Demir, Esin; Atar, Bilge; Dhawan, Dipali; Barh, Debmalya; Gündüz, Mehmet; Gündüz, Esra
    Omics technologies are powerful high-throughput analytic tools to get inside whole-system level alterations of cancer cells. Since cancer stem cells are groups of vital cells in heterogeneous tumor populations, their omics analysis will enable better understanding in most controversial issues. These issues are mostly treatment resistance and metastatic ability of tumors. The relation between breast cancer patients' survival rates and stem cells in breast tumor has revealed the significance of breast cancer stem cells. The high tumor-forming capacity of these stem cells makes it necessary to get more comprehensive insight about their biology. Genomics, proteomics, and epigenomics are helpful tools for this purpose. The general step of these high-throughput methods is the isolation of breast cancer stem cells based on specific markers. Another shared feature of these omics approaches is to use a large set of interested genes, transcripts, or proteins. In addition to these two common key features, the remaining experimental setups may change from one to another omics analysis. The outcome of these approaches can yield some signatures, which will be mostly critical for later therapeutic strategies. Taken altogether, omics approaches not only reveal comprehensive understanding about breast cancer stem cells but also open the doors to more effective targeted therapies. © 2015 Elsevier B.V., All rights reserved.
  • Küçük Resim Yok
    Öğe
    Cancer Biomarkers Minimal and Noninvasive Early Diagnosis and Prognosis Preface
    (Crc Press-Taylor & Francis Group, 2014) Barh, Debmalya; Carpi, Angelo; Verma, Mukesh; Gunduz, Mehmet
    [Abstract Not Available]
  • Küçük Resim Yok
    Öğe
    Cancer biomarkers: Minimal and noninvasive early diagnosis and prognosis
    (CRC Press, 2014) Barh, Debmalya; Carpi, Angelo; Verma, Mukesh; Gündüz, Mehmet
    Gleaning information from more than 100 experts in the field of cancer diagnosis, prognosis, and therapy worldwide, Cancer Biomarkers: Non-Invasive Early Diagnosis and Prognosis determines the significance of clinical validation approaches for several markers. This book examines the use of noninvasive or minimally invasive molecular cancer markers that are under development or currently in use. It deals with a majority of commonly prevalent cancers and can help anyone working in the health-care industry to recommend or develop early diagnostics, at-risk tests, and prognostic biomarkers for various cancers. It explores the practice of determining biomarkers by their characteristics and relative methodologies, and presents the most recent data as well as a number of current and upcoming early diagnostic noninvasive molecular markers for many common cancers. It also considers the sensitivity and specificity of markers, biomarker market, test providers, and patent information. Approximately 30-35 Cancer Specific Noninvasive Molecular Diagnostic Markers in a Single Volume The book details the general and technical aspects of noninvasive cancer markers. It covers imaging, cutting-edge molecular technologies for biomarker development, and noninvasive or minimally invasive sources of molecular markers, as well as quality control and ethical issues in cancer biomarker discovery. It also provides a detailed account of brain, head and neck, and oral cancer markers, and provides information on a number of gastrointestinal cancers, lung cancer, and mesothelioma markers. Emphasizes the Importance of Volatile Markers in Early Cancer Diagnosis • Presents noninvasive early molecular markers in urological cancers • Describes gynecological and endocrine cancer markers • Details noninvasive markers of breast, ovarian, cervical, and thyroid cancers • Addresses hematological malignancies • Contains information on noninvasive molecular markers in myelodysplastic syndromes, acute myeloid leukemia, Hodgkin’s lymphoma, and multiple myeloma • Provides comprehensive information on diagnostic and prognostic biomarkers in cutaneous melanoma This text considers molecular technologies for biomarker development, noninvasive or minimally invasive sources of molecular markers, and quality control and ethical issues in cancer biomarker discovery. © 2018 Elsevier B.V., All rights reserved.
  • Küçük Resim Yok
    Öğe
    Omics of male breast cancer
    (Springer India, 2014) Ünal, Zahide Nur; Kaya, Gülhan; Barh, Debmalya; Gündüz, Esra; Gündüz, Mehmet
    Male breast cancer (MBC) is rarely diagnosed. However, it has relatively poor prognosis when compared to female breast cancer. Although the importance of genetic predisposition in MBC etiology has been considerably understood, a wide range of gene and protein alterations playing various roles in MBC carcinogenesis point at its polygenic nature rather than single gene inheritance. Therefore, more comprehensive approaches including omics study and related technologies are required to thoroughly manage this malignancy, though such studies have been scarcely performed in MBC. © 2015 Elsevier B.V., All rights reserved.